Opus Genetics (IRD) FCF Margin (2020 - 2026)
Opus Genetics (IRD) posted quarterly FCF Margin of 590.03% for Q1 2026, down 38422.0% year-over-year from N/an in Q1 2025, and down 131.92% quarter-over-quarter from 254.41% in Q4 2025.
Opus Genetics (IRD) FCF Margin (2020 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported FCF Margin for 7 consecutive years, with 590.03% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 38422.0% year-over-year to 590.03%; the TTM figure through Mar 2026 stood at 325.34% (down 11398.0% YoY), while the FY2025 annual figure was 248.33%, down 1565.0% from the prior year.
- FCF Margin eased to 590.03% in Q1 2026 per IRD's latest filing, from 254.41% in the prior quarter.
- Across five years, FCF Margin topped out at 268.95% in Q4 2023 and bottomed at 655.76% in Q2 2024.
- Historically, FCF Margin has averaged 197.67% across 5 years, with a median of 202.89% in 2025.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 68267 bps — and 2025, when it soared 29944 bps.
- Opus Genetics' FCF Margin stood at 72.25% in 2022, then soared by 272 bps to 268.95% in 2023, then plunged by 164 bps to 172.9% in 2024, then slumped by 47 bps to 254.41% in 2025, then slumped by 132 bps to 590.03% in 2026.
- Business Quant data shows IRD's FCF Margin at 590.03% in Q1 2026, 254.41% in Q4 2025, and 199.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -1,582.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,582.78% |
| Mar 31, 2026 | -590.03% |
| Dec 31, 2025 | -254.41% |
| Sep 30, 2025 | -199.97% |
| Jun 30, 2025 | -356.32% |
| Mar 31, 2025 | -205.81% |
| Dec 31, 2024 | -172.90% |
| Sep 30, 2024 | -132.66% |
| Jun 30, 2024 | -655.76% |
| Mar 31, 2024 | -334.07% |
| Dec 31, 2023 | 268.95% |
| Sep 30, 2023 | -25.16% |
| Jun 30, 2023 | 26.92% |
| Mar 31, 2023 | -208.46% |
| Dec 31, 2022 | 72.25% |
| Sep 30, 2021 | -732.92% |
| Jun 30, 2021 | -4,328.00% |
| Mar 31, 2020 | -63.65% |